Description
Mirvetuximab soravtansine-gynx (Elahere) is a folate receptor alpha (FR)-directed antibody and microtubule inhibitor conjugate indicated for the treatment of adult patients with FR positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer, who have received one to three prior systemic treatment regimens.
Mirvetuximab soravtansine (Elahere) can cause severe ocular toxicities including visual impairment, dry eye, photophobia, eye pain, and uveitis; prophylactic lubricating eye drops and topical ophthalmic steroids are recommended during treatment.